Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Sunshine Biopharma Inc. Warrant (SBFMW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: SBFMW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -100% | Avg. Invested days 15 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.96 | 52 Weeks Range 0.05 - 0.98 | Updated Date 05/25/2025 |
52 Weeks Range 0.05 - 0.98 | Updated Date 05/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.21 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -13.88% | Operating Margin (TTM) -14.56% |
Management Effectiveness
Return on Assets (TTM) -11.78% | Return on Equity (TTM) -21.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 4553895 |
Shares Outstanding - | Shares Floating 4553895 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Sunshine Biopharma Inc. Warrant
Company Overview
History and Background
Sunshine Biopharma Inc. is a pharmaceutical company focused on the research and development of oncology and antiviral drugs. The warrants represent the right to purchase common shares of Sunshine Biopharma. The company was founded in 2006.
Core Business Areas
- Pharmaceutical Development: Focuses on the development of cancer therapies, with a particular emphasis on mRNA-based drugs. Also develops antiviral treatments.
Leadership and Structure
The leadership team consists of experienced scientists and executives in the pharmaceutical industry. The organizational structure typically involves research and development, regulatory affairs, and business development departments.
Top Products and Market Share
Key Offerings
- Adva-27a: This is a small molecule drug designed to treat pancreatic cancer. Market share data for this specific product is not widely available. Competitors include major pharmaceutical companies developing pancreatic cancer treatments such as Eli Lilly and Roche.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. It involves significant research and development costs, clinical trials, and regulatory approvals. The oncology and antiviral drug markets are growing due to increasing cancer incidence and emerging viral threats.
Positioning
Sunshine Biopharma is a smaller player in the pharmaceutical industry, focusing on niche areas such as mRNA-based cancer therapeutics. Its competitive advantage lies in its innovative drug candidates and research focus.
Total Addressable Market (TAM)
The global oncology drug market is projected to reach hundreds of billions of dollars. Sunshine Biopharma targets a portion of this market, particularly pancreatic cancer, with its Adva-27a candidate.
Upturn SWOT Analysis
Strengths
- Innovative mRNA-based drug development
- Focus on specific cancer types
- Experienced research team
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- Small market capitalization
Opportunities
- Partnerships with larger pharmaceutical companies
- Successful clinical trial outcomes
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Funding challenges
Competitors and Market Share
Key Competitors
- MRNA
- PFE
- BMY
Competitive Landscape
Sunshine Biopharma faces intense competition from larger, established pharmaceutical companies with greater resources and broader product portfolios. Their advantage is specialized cancer drugs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been dependent on research milestones and funding.
Future Projections: Future growth depends on successful clinical trials and commercialization of its drug candidates.
Recent Initiatives: Recent initiatives often involve advancing clinical trials and seeking partnerships.
Summary
Sunshine Biopharma is a small pharmaceutical company with innovative mRNA-based drug development programs, especially in cancer treatment. Its strengths lie in its research focus. Its weaknesses include limited resources and dependence on clinical trial success. Success depends on obtaining funding, partnerships, and navigating regulatory hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Market research reports
- Financial news sources
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sunshine Biopharma Inc. Warrant
Exchange NASDAQ | Headquaters Fort Lauderdale, FL, United States | ||
IPO Launch date 2022-02-15 | Chairman, President & CEO Dr. Steve N. Slilaty Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 52 | Website https://sunshinebiopharma.com |
Full time employees 52 | Website https://sunshinebiopharma.com | ||
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.